海思科(002653.SZ)创新药环泊酚注射液获拓展儿童人群批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for a supplemental application regarding the use of its drug, Ropivacaine Injection, specifically for pediatric and adolescent anesthesia [1] Group 1 - The subsidiary, Shenyang Haishike Pharmaceutical Co., Ltd., is the entity that received the approval [1] - The approved supplemental application includes indications for the use of Ropivacaine Injection in the induction and maintenance of general anesthesia in children and adolescents [1] - The approval also involves revisions to the safety information in the drug's instructions [1]